PTEN loss does not predict for response to RAD001 (everolimus) in a glioblastoma orthotopic xenograft test panel

Clinical Cancer Research

Volumn 14, Issue 12, 2008, Pages 3993-4001

  Yang, Lin ^a   Clarke, Michelle J ^a   Carlson, Brett L ^a   Mladek, Ann C ^a   Schroeder, Mark A ^a   Decker, Paul ^a   Wu, Wenting ^a   Kitange, Gasparj ^a   Grogan, Patrickt ^a   Goble, Jennie M ^a   Uhm, Joon ^a   Galanis, Evanthia ^a   Giannini, Caterina ^a   Lane, Heidi A ^b   James, C David ^c   Sarkaria, Jann N ^a,d  

^a MAYO CLINIC   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME PHOSPHORYLATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; APOPTOSIS; BRAIN TUMOR; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; GENETICS; HETEROTOPIC TRANSPLANTATION; METABOLISM; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PROGNOSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CELL PROLIFERATION; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROTEIN KINASES; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIROLIMUS; TRANSPLANTATION, HETEROTOPIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 52449131427     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4152     Document Type: Article

References (42)

1. Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005;23:5314-22.
2. Hudes G, Carducci M.Tomczak P, et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271 -81.
3. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005;23:5347-56.
4. Rao RD, BucknerJC, SarkariaJN. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. Curr Cancer DrugTargets 2004;4:621 -35.
5. Sekulic A, Hudson CC, Homme JL, et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 2000;60:3504-13.
6. Inoki K, Li Y, Zhu T,Wu J, Guan KL.TSC2 is phosphor-ylated and inhibited byAkt and suppresses mTOR signalling. Nat Cell Biol 2002;4:648-57.
7. Manning BD.TeeAR, Logsdon MN, BlenisJ, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 2002;10:151-62.
8. Potter CJ, Pedraza LG, XuT. Akt regulates growth by directly phosphorylatingTsc2. Nat Cell Biol 2002;4:658-65.
9. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci 2001;98: 10314-9.
10. Shi Y, Gera J, Hu L, et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 2002;62:5027-34.
11. Podsypanina K, Lee RT, Politis C, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci 2001;98:10320-5.
12. Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, Thomas G. Mammalian TOR: a homeostatic ATP sensor. Science 2001;294:1102-5.
13. Nave BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 1999;344:427-31.
14. Hara K.Yonezawa K.Weng Q-P, Kozlowski MT, Belham C, Avruch J. Amino acid sufficiency and mTOR regulate p70 S6 kinase and elF-4E BP1 through a
15. common effector mechanism. J Biol Chem 1998:273:14484-94.
16. Patel J, Wang X, Proud CG. Glucose exerts a permissive effect on the regulation of the initiation factor 4E binding protein 4E-BP1. Biochem J 2001:358:497-503.
17. Arsham AM, Howell JJ, Simon MC. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 2003:278:29655-60.
18. Long X, Ortiz-Vega S, LinY, Avruch J. Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency. J Biol Chem 2005;280:23433-6.
19. Brugarolas J, Lei K, Hurley RL, et al. Regulation of mTOR function in response to hypoxia by REDD1 and theTSC1/TSC2 tumor suppressor complex. Genes Dev 2004;18:2893-904.
20. Sofer A, Lei K, Johannessen CM, Ellisen LW. Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol Cell Biol 2005;25:5834-45.
21. Thomas GV.Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006;12:122-7.
22. Sarkaria JN, Yang L, Grogan PT, et al. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther 2007;6:1167-74.
23. Sarkaria JN, Carlson BL, Schroeder MA, et al. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res 2006;12:2264-71.
24. Whang YE, Wu X, Suzuki H, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci 1998;95:5246-50.
25. Wei Q, Bondy ML, Mao L, et al. Reduced expression of mismatch repair genes measured by multiplex reverse transcription-polymerase chain reaction in human gliomas. Cancer Res 1997;57:1673-7.
26. Eshleman J, Carlson B, Mladek A, Kastner B, Shide K, Sarkaria J. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 2002:62:7291 -7.
27. Pandita A, Aldape KD, Zadeh G, Guha A, James CD. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 2003;39:29-36.
28. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005;23:5294-304.
29. Chang SM.Wen P, CloughesyT, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005;23:357 - 61.
30. Shinohara ET, Cao C, Niermann K, et al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 2005;24:5414-22.
31. Lang SA, Gaumann A, Koehl GE, et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. IntJ Cancer 2007;120:1803-10.
32. Laschke MW, Elitzsch A, Scheuer C, Holstein JH, Vollmar B, Menger MD. Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation. Br J Pharmacol 2006:149: 137-44.
33. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35.
34. Houchens DP, Ovejera AA, Riblet SM, Slagel DE. Human brain tumor xenografts in nude mice as a chemotherapy model. Eur J Cancer 1983;19:799-805.
35. Goudar RK, Shi Q, Hjelmeland MD, et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol CancerTher 2005;4:101 -12.
36. Heimberger AB, Wang E, McGary EC, et al. Mechanisms of action of rapamycin in gliomas. Neuro-oncol 2005;7:1 -11.
37. Geoerger B, Kerr K.Tang C-B, et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 2001;61:1527-32.
38. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5:671 -88.
39. Choe G, Horvath S, CloughesyTF, et al. Analysis of the phosphatidylinositol 3́-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 2003:63:2742 - 6.
40. Jiang R, Mircean C, Shmulevich I, et al. Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays. Proteomics 2006;6:2964-71.
41. Riemenschneider MJ, Betensky RA, Pasedag SM, Louis DN. AKT activation in human glioblastomas enhances proliferation viaTSC2 and S6 kinase signaling. Cancer Res 2006;66:5618-23.
42. Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A 2005;102:8204-9.